Zymeworks Inc. will focus on achieving the following in 2019: Initiating multiple Phase 2 studies for ZW25 - Expanding the global clinical development of ZW25 into Asia and Europe - Reporting ZW25 data from combination studies (chemotherapy and/or targeted agents) - Reporting data from the Phase 1 trial for ZW49 - Establishing additional drug development collaborations with a focus on new platforms.